Compare Berkshire Hathaway Inc Class B (BRK.B) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Incyte Corporation — how do they compare? Berkshire Hathaway Inc Class B trades at $511.07, while Incyte Corporation trades at $120.77 (market cap $24.48B). Which is the better fit depends on your goals.
| BRK.B | INCY | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $529.65 | $129.93 |
52-Week Low | $465.39 | $81.66 |
Market Cap | — | $24.48B |
Enterprise Value | — | $19.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $516.22, down 2.54% today amid broader market weakness. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Analyst consensus leans positive with 57% buy ratings and no sell recommendations. The stock maintains strong institutional support and benefits from Berkshire Hathaway's diversified business model.
The long-term outlook remains favorable given Berkshire's strong cash position and diversified holdings. Key risks include market volatility and economic sensitivity, but the company's defensive characteristics and management quality provide stability. Current levels offer entry opportunity for value-oriented investors seeking quality exposure.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
